Roche to Acquire Carmot Therapeutics in a $3.1 Billion Deal
Roche to acquire Carmot Therapeutics for $3.1B, gaining access to innovative obesity and diabetes treatments. The deal includes clinical-stage assets with potential for standalone and combination therapies. Expected to close in Q1 2024, pending regulatory approval.